Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay.

Published in: Clinical trials (London, England) (2020)

With an imperfect biomarker assay, the decision to apply a biomarker-based outcome-adaptive randomization design may require careful reflection.

Keyphrases